Polyrizon Ltd.

General Information

(Note:  This is a unit IPO consisting of 1.35 million units. Each unit consists of one share  of  stock and three warrants, each to purchase one ordinary shares. Polyrizon Ltd. filed its F-1 on Aug. 10, 2022.)

We are a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Our proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. We are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. We refer to our additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T.

 Our nasal hydrogels have been designed to serve as a non-invasive and fast-acting system. The hydrogels are formulated as an innovative mixture of mucoadhesive polymers (e.g., sodium alginate) which are Generally Recognized as Safe, or GRAS, by the Federal Drug Administration, or the FDA. Our mucoadhesive polymers derived from seaweed polysaccharides possess promising features as they are renewable, biodegradable, biocompatible, and environment friendly. The formulated hydrogel is sprayed into the nose to create a physical barrier with long-lasting adhesion to the mucosal membranes. Our polymers have an atomic mass much higher than the upper cell penetration limit, the polymers will simply lay on top of the cells and act as a physical barrier to viruses and allergens from contacting the nasal epithelial tissue, as opposed to penetrating the cells and causing a chemical reaction. Therefore, the C&C product candidates are not expected to be considered as drugs by the FDA but as medical devices.

Employees: 5
Founded: 2005
Contact Information
Address I5 Ha-Tidhar Street Raanana, 4366507, Israel
Phone Number 972-9-9374333
Web Address http://www.polyrizon-biotech.com/
View Prospectus: Polyrizon Ltd.
Financial Information
Market Cap $35.1mil
Revenues $0 mil (last 12 months)
Net Income $-1.15 mil (last 12 months)
IPO Profile
Symbol PLRZ
Exchange NASDAQ
Shares (millions): 1.4
Price range $5.20 - $7.20
Est. $ Volume $8.4 mil
Manager / Joint Managers Aegis Capital Corp.
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change